Siemens Healthineers AG (OTCMKTS:SMMNY) Receives Average Rating of “Buy” from Analysts

Shares of Siemens Healthineers AG (OTCMKTS:SMMNY) have been given a consensus rating of “Buy” by the seven brokerages that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, two have given a buy rating and three have given a strong buy rating to the company.

Several research firms have issued reports on SMMNY. Royal Bank Of Canada assumed coverage on Siemens Healthineers in a report on Wednesday, December 17th. They issued a “moderate buy” rating on the stock. Deutsche Bank Aktiengesellschaft cut Siemens Healthineers from a “buy” rating to a “hold” rating in a report on Thursday, December 4th. Finally, Zacks Research raised Siemens Healthineers from a “strong sell” rating to a “hold” rating in a report on Monday.

Siemens Healthineers Stock Up 0.6%

Shares of SMMNY opened at $27.33 on Friday. The firm’s 50 day moving average is $25.58 and its 200-day moving average is $26.86. Siemens Healthineers has a 12-month low of $23.28 and a 12-month high of $30.19.

About Siemens Healthineers

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.